Monoamine Contributions to Neurocircuitry in Eating Disorders
- Conditions
- Eating Disorder
- Interventions
- Registration Number
- NCT02020408
- Lead Sponsor
- University of California, San Diego
- Brief Summary
This study will use brain imaging technologies to measure several neurotransmitters (serotonin and dopamine) that contribute to our abilities to respond to reward or inhibit our impulses, and which are known to be altered in the brain of people with anorexia nervosa (AN) and bulimia nervosa (BN). Because palatable food stimulates dopamine secretion, we propose to use a challenge with brain imaging that will stimulate dopamine release which we hypothesize will generate anxiety rather than pleasure in AN, and will help explain why AN restrict eating in order to reduce anxiety. This study will help to understand the unique puzzling symptoms in eating disorders and contribute to finding better methods for identifying effective treatments for these often relapsing and sometimes chronic disorders.
- Detailed Description
Alterations of serotonin (5-HT) and dopamine (DA) activity may contribute to extremes of appetitive behaviours in anorexia nervosa (AN) and bulimia nervosa (BN), through effects on inhibitory and reward neural pathways. To avoid the confounding effects of malnutrition, and because they have behaviours and neural circuit alterations relevant for this study, we will study 25 recovered (REC) restricting-type AN, 25 REC bulimic-type AN (AN-BN), 25 REC BN, and 25 control women (CW). This 5 year study, of women 18 to 45 years old, will employ positron emission tomography (PET) imaging with radioligands for the 5-HT transporter (\[11C\]DASB) and DA D2/D3 receptors (\[11C\]raclopride).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 88
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [11C]raclopride, [11C]DASB, amphetamine [11C]DASB One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using \[11C\]DASB. Two PET scans using \[11C\]raclopride. [11C]raclopride, [11C]DASB, amphetamine [11C]raclopride One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using \[11C\]DASB. Two PET scans using \[11C\]raclopride. [11C]raclopride, [11C]DASB, amphetamine amphetamine One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using \[11C\]DASB. Two PET scans using \[11C\]raclopride.
- Primary Outcome Measures
Name Time Method 5-HT Transporter Binding as Measured During the PET Scan 90 minute PET scan Use PET and \[11C\]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes.
The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. \[VT = distribution volume in tissue; VND = non-displaceable distribution volume\]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity.
- Secondary Outcome Measures
Name Time Method Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration 90 min PET scan Use PET and \[11C\]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. \[VT = distribution volume in tissue; VND = non-displaceable distribution volume\].
Trial Locations
- Locations (1)
University of California San Diego
🇺🇸San Diego, California, United States